“Any sufficiently advanced technology is indistinguishable from magic."

– Arthur C. Clarke

A woman with curly blonde hair wearing a red dress and a silver necklace, smiling, standing in front of a yellow wall with a microphone in front of her.

Hi, I’m Dr. Samantha Meenach.

Founder of ScienceLife Collective and Professor of Chemical Engineering and Biomedical and Pharmaceutical Sciences at the University of Rhode Island. My research sits at the intersection of pharmaceutical sciences, biomedical engineering, and nanomedicine, and I have spent more than a decade building a technically diverse drug delivery research program. I established ScienceLife Collective to bring that depth of expertise directly to attorneys, pharmaceutical companies, and research organizations navigating complex scientific questions in litigation and advisory contexts.

Credentials at a glance

Person holding a black graduation cap with a gold tassel in front of a large, ornate building with multiple windows and decorative architectural details.

  • Professor, University of Rhode Island, Chemical Engineering & Biomedical and Pharmaceutical Sciences

  • $5M+ in competitive federal research funding (NIH, NSF)

  • 36 peer-reviewed publications, 17 as corresponding author

  • 10+ years as a principal investigator at URI

  • Active NIH and NSF-funded research as of 2026

About Me

My CV

  • My credentials are specific, current, and independently verified. I hold a joint faculty appointment across two departments, reflecting the cross-disciplinary nature of my expertise. My research program has been continuously funded by the National Institutes of Health and the National Science Foundation, with more than $5 million in competitive federal awards. I have authored 36 peer-reviewed publications, 17 of which I served as corresponding author, demonstrating independent scientific leadership rather than team participation. My research is active and ongoing, which means opposing counsel cannot challenge me on recency. I am not a professional expert witness who has drifted from active science. I am a working researcher who also testifies.

  • My active research spans pulmonary drug delivery, nanoparticle systems, biomaterials, pharmaceutical stability, cancer therapeutics, and aerosol science. In the litigation context, that translates to a broad range of case types including pharmaceutical product liability, pharmacy dispensing errors, drug stability and expiration dating disputes, medical device and biomaterial failures, nanotechnology patent matters, and research misconduct. I am one of a very small number of testifying experts who can speak credibly across both pharmaceutical sciences and biomedical engineering without overreaching.

  • I earned my doctorate in chemical engineering and went on to build a research program at URI focused on developing next-generation drug delivery systems for serious diseases including lung cancer, cystic fibrosis, and pulmonary hypertension. Over more than a decade at URI, I have mentored dozens of undergraduate and graduate researchers, directed NIH-funded training programs, and published across multiple disciplines. That breadth is not accidental. It reflects a deliberate commitment to working at the edges of what pharmaceutical science and biomedical engineering can do together. ScienceLife Collective is an extension of that same commitment, applied to the legal and advisory context.